Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fisca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback